Ampio Pharmaceuticals Inc. (AMPE) shares gained 11.57% in after-hours on Wednesday, August 04, 2021, and closed at $1.35 per share. however, in the regular trading session of Wednesday, AMPE’s stock lost 8.33%. The stock volume remained 3.3 million shares, which was higher than the average daily volume of 2.05 million shares within the past 50 days. AMPE shares have risen 9.01% over the last 12 months, and they have moved down 14.79% in the past week. Over the past three months, the stock has lost 32.78%, while over the past six months, it has declined 30.46%.
Let’s see is there any recent news about the company?
AMPE recent financial results announcement
On August 4, 2021, Ampio Pharmaceuticals, Inc. (AMPE), reported its financial results for the second quarter period ended June 30, 2021.
Q2 2021 financial highlights
- AMPE suffered a net loss of $3.56 million in Q2 2021 or basic and diluted loss per share of $0.02 in Q2 2021 compared to $2.7 million net loss or basic and diluted loss per share of $0.02 in Q2 2020.
- Total operating expenses were $3.64 million for Q2 2021 compared to $2.6 million in Q2 2020.
- As of June 30, 2021, the company had cash and cash equivalents totalled $20.5 million, compared to $17.3 million on December 31, 2020.
AMPE Participation in the upcoming conferences
- AMPE announced to do a poster presentation at the 63rd annual Thomas L. Petty Aspen Lung Conference which will be held on September 20 to 23, 2021, at the Gant Conference Center in Aspen, Colorado. The topic of the poster presentation is “Inflammation and COVID Induced ARDS: Inhaled Ampion™ as a Therapeutic Option”.
- Ampio Pharmaceuticals will do an abstract presentation virtually at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & the 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA) on October 6-9, 2021. The topic of the abstract is “Significant Inhibition of the TLR7/CXCL10 Signaling Axis by LMWF5A in Monocytic Lineages; Implications for COVID-19 and Lupus Nephritis,”
- The company will also participate virtually at the upcoming American College of Toxicology 42nd Annual Meeting, which will be held on November 14 to 17, 2021, at the Gaylord National Harbor in Washington, DC. AMPE will do a poster presentation about “Efficient Applied Toxicology during COVID-19: A Preclinical Study that Advanced Clinical Use of Ampion”.
AMPE provide an update about Ampion™ Phase II clinical trial
On June 25, 2021, Ampio Pharmaceuticals announced randomization and dosing of patients in its multi-centre AP-019 Phase II clinical trial, using inhaled Ampion™ in the treatment of respiratory distress due to COVID-19, is underway.
Ampion interrupts the hyperactive immune response associated with COVID-19 and may improve the clinical outcome for patients suffering from its complications because it contains an immunomodulatory agent with anti-inflammatory effects.
Conclusion
We have only one recent news which is AMPE Q2 2021 financial results which could be the reason behind its turnaround in the after-hours on Wednesday.
